Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jul. 01, 2012		Jul. 03, 2011
Cash flows from operating activities:
Net loss	$ (158,711)		$ (149,993)
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation	23,908		25,980
Depreciation	58,362		53,664
Loss on retirement of property, plant and equipment	45,409		0
Amortization of other intangible assets	5,477		13,932
Gain on sale of investments	0		191
Loss (gain) on mark-to-market derivatives	(4)		141
Non-cash interest expense	15,346		14,332
Amortization of debt issuance costs	1,880		2,734
Amortization of promissory notes	0		3,352
Gain on change in equity interest in unconsolidated investee	0		(322)
Third-party inventories write-down	8,869		16,399
Project assets write-down	0		16,053
Equity in earnings (loss) of unconsolidated investees	2,350		(6,961)
Deferred income taxes and other tax liabilities	2,663		(2,084)
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable	156,973		3,109
Costs and estimated earnings in excess of billings	(13,736)		(47,114)
Inventories	(13,090)		(102,997)
Project assets	(39,246)		(83,842)
Prepaid expenses and other assets	(177,857)		(9,328)
Advances to suppliers	(18,320)		(17,470)
Accounts payable and other accrued liabilities	(60,429)		(16)
Billings in excess of costs and estimated earnings	(25,167)		(2,480)
Customer advances	4,095		(7,812)
Net cash used in operating activities	(181,228)		(280,532)
Cash flows from investing activities:
Decrease in restricted cash and cash equivalents	51,621		30,693
Purchase of property, plant and equipment	(62,644)		(68,164)
Proceeds from sale of equipment to third-party	419		499
Proceeds from sales or maturities of available-for-sale securities	0		43,759
Cash received for sale of investments in joint ventures	17,403		0
Cash paid for investments in joint ventures	(10,000)		(50,000)
Net cash used in investing activities	(3,201)		(43,213)
Cash flows from financing activities:
Proceeds from issuance of bank loans, net of issuance costs	125,000		189,221
Proceeds from issuance of project loans, net of issuance costs	13,787		0
Proceeds from residential lease financing	8,247		0
Repayment of bank loans and other debt	(101,132)		(226,136)
Cash paid for repurchase of convertible debt	(198,608)		0
Proceeds from private offering of common stock, net of issuance costs	163,681		0
Cash distributions to Parent in connection with the transfer of entities under common control	(178,290)		0
Proceeds from exercise of stock options	34		3,926
Purchases of stock for tax withholding obligations on vested restricted stock	(5,204)		(9,396)
Net cash provided by (used in) financing activities	(172,485)		(42,385)
Effect of exchange rate changes on cash and cash equivalents	(2,454)		6,500
Net decrease in cash and cash equivalents	(359,368)		(359,630)
Cash and cash equivalents at beginning of period	725,618	[1]	605,420
Cash and cash equivalents, end of period	366,250		245,790
Non-cash transactions:
Assignment of financing receivables to a third party financial institution	2,523		0
Property, plant and equipment acquisitions funded by liabilities	12,124		6,494
Non-cash interest expense capitalized and added to the cost of qualified assets	750		1,294
Issuance of warrants in connection with the Liquidity Support Agreement	$ 50,327		$ 0

[1] As adjusted to reflect the balances of Tenesol S.A. ("Tenesol") beginning October 10, 2011, as required under the accounting guidelines for a transfer of an entity under common control (see Note 3).